- Home
- ATYR vs TNGX Comparison
ATYR vs TNGX Comparison
Compare ATYR & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ATYR | TNGX |
|---|---|---|
| Founded | 2005 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 49.2M | 4.1B |
| IPO Year | 2015 | 2020 |
Fundamental Metrics
Financial Performance| Metric | ATYR | TNGX |
|---|---|---|
| Price | $0.36 | $21.98 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 9 | 10 |
| Target Price | $3.67 | ★ $21.78 |
| AVG Volume (30 Days) | 728.9K | ★ 2.1M |
| Earning Date | 05-01-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 6.98 | ★ 26.89 |
| EPS | ★ N/A | N/A |
| Revenue | $190,000.00 | ★ $62,384,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 48.29 |
| 52 Week Low | $0.37 | $6.69 |
| 52 Week High | $1.12 | $34.39 |
Technical Indicators
Market Signals| Indicator | ATYR | TNGX |
|---|---|---|
| Relative Strength Index (RSI) | 25.85 | 37.46 |
| Support Level | N/A | $21.20 |
| Resistance Level | $0.59 | $25.64 |
| Average True Range (ATR) | 0.03 | 1.27 |
| MACD | -0.01 | 0.09 |
| Stochastic Oscillator | 2.13 | 11.45 |
Price Performance
Historical ComparisonAbout ATYR aTyr Pharma Inc.
aTyr Pharma Inc is a clinical-stage biotechnology company focused on developing therapies for fibrosis and inflammatory conditions. Its research leverages tRNA synthetase biology to identify potential therapeutic targets. The company's discovery platform uses a proprietary library of domains derived from tRNA synthetases to explore signaling pathways. Its flagship clinical candidate, efzofitimod, is a novel biologic immunomodulatory in development for the treatment of interstitial lung disease (ILD).
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.